SPONSORED CONTENT by Jerry Buller
The challenges that ‘white bagging’ poses for patients and providers are gaining attention as more health plans mandate these policies. ‘White bagging’ disrupts traditional ‘buy-and-bill’ practices for provider-administered drugs, creating patient safety concerns, operational problems, and financial challenges for covered entities.
SPONSORED CONTENT by Kristin Fox-Smith and William Wood, Visante
Those of us actively engaged in the 340B Program are well aware of the scores of issues faced by participating hospitals and it’s not surprising since they account for an exceptionally large percentage of all HRSA audits. But, what about other types
…SPONSORED CONTENT
The devastating double-whammy of Medicare Part B payment cuts and COVID-19 has again highlighted the 340B program’s significance to hospital finance. Once relegated to the hospital’s basement pharmacy, the 340B program is increasingly a topic of boardroom and C-suite discussions.
In the latest episode of Omnicell’s The Future of Pharmacy podcast, learn
…
Eli Lilly and AstraZeneca are the latest drug makers to disclose they have received a subpoena from the Vermont attorney general’s office related to their denials of 340B ceiling prices on drugs shipped to contract pharmacies.
SPONSORED CONTENT by Ross Halsne
It’s becoming increasingly difficult for Covered Entities (CEs) to effectively manage their 340B pharmacy programs. Often times understaffed relative to the task of handling the myriad of challenges that come with managing a 340B program, they face a seemingly constant barrage of maneuvering and attacks aimed at reducing their 340B benefit. In response, many Covered Entities are evaluating new strategies to strengthen or reinvigorate
…There are several ways to enhance, boost, and optimize 340B savings. This white paper looks at how capturing referrals can benefit a covered entity’s 340B program savings and mission.
HRSA GUIDELINES REGARDING REFERRALS
According to HRSA guidelines, a covered entity may send a patient to an outside clinic not registered with 340B and consider
…SPONSORED CONTENT
Do you provide clinical care for patients living with or at risk of HIV? If so, you know how important it is to consider their needs beyond the clinic visit.
The patient journey is not linear. Social stigma, family issues, mental health challenges, financial hardship,
…
Acentrus Specialty hosted its first Acentrus Specialty Conference on January 12-13, 2021, which brought together pharmacists, manufacturers, and suppliers to examine the challenges, opportunities, and best practices in advancing health system specialty pharmacy practice. A pharmacy paradigm shift is under way, as Integrated Delivery Networks (IDNs) are partnering to grow their specialty pharmacy operations.
“The conference
…
Pharmaceutical Research and Manufacturers of America (PhRMA) sued yesterday in federal district court in Maryland to strike down the federal final rule that established the new 340B program administrative dispute resolution (ADR) process. It also wants the court to declare
…340B Report’s content including full articles is now available exclusively for paid subscribers. For those who have already paid, we sincerely thank you. If you have any questions about logging in, please contact Reshma Eggleston at reshma.eggleston@340Breport.com
For those who have not
*Sign up for news summaries and alerts from 340B Report
